April 9, 2018 / 11:01 AM / 13 days ago

Merck's Keytruda meets main goal in lung cancer trial

April 9 (Reuters) - Merck & Co said on Monday a late-stage trial testing its blockbuster cancer drug, Keytruda, met the main goal of helping previously untreated lung cancer patients live longer.

The trial tested Keytruda as a monotherapy to treat non-small cell lung cancer.

The company’s shares rose 2.6 percent to $54.75 in premarket trading. (Reporting by Tamara Mathias in Bengaluru; Editing by Sriraj Kalluvila)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below